1. In Vivo
  2. >>New Science

Science Matters: Harnessing The Inherent Power Of MAIT Cells

 
• By Mark Ratner

Tapping into the interplay between gut microbiota and an underappreciated subset of T cells could lead to therapies in a range of diseases.  

• Source: Shutterstock

A publication in the May 25th issue of Science Translational Medicine (STM) suggests that gut microbiota may activate a type of unconventional T cell called MAIT (mucosal-associated invariant T cell) in cancer patients receiving allogeneic hematopoietic cell transplantation (allo-HCT). The paper suggests a link between the presence of MAIT cells, as well as another so-called unconventional T cell, and reduced risk of graft-versus-host disease (GVHD), a serious complication of allogeneic transplantation.

The paper is part of a growing body of recent literature around MAIT cells, whose functions are not clearly understood but where evidence is pointing to their potential role in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Science

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

Lighting The Way To Anxiety Treatments With No Side Effects

 
• By Ian Taylor

Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By David Wild

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

From Brain Waves to Better Outcomes: Inside Alto Neuroscience’s Biomarker Strategy

 
• By David Wild

Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.

More from In Vivo

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.